Autumn 2024
Signs of recovery
The first half of 2024 is history, and experts are divided on whether the financing nadir has been reached or even passed. There are very different figures for different types of treatments under development. ADCs and radioligands are on the rise, while cell and gene therapies are way down. Are larger financing rounds and a few IPOs a good sign for all? Some European companies hit the jackpot, but most still struggle. Amidst the positive news, one major uncertainty remains: interest rates.
In this issue:
- Cover story: M&A and IPOs resurrection ahead?
- Survey: Industry leaders adopt synbio and AI across eleven sectors
- Alternative protein investments: Cell and plant-based down, fermentation up
- Von der Leyen defines priorities for the European Commission’s next term
- SLAS Europe: Innovation in lab automation drives transformation in the biopharmaceutical industry
- European Medicines Agency: Aplidin – a politically motivated scandal?
- RNA Drugs – A second RNAissance
- Bacterial cure for chemotherapy; Turning down immune response; Immune system-on-a-chip; Alcohol antidote; AdEs of obesity drugs
- Regional news, news from BIOTECH Austria, Society for Laboratory Automation and Screening (SLAS) and the Young European Biotech Network
- SPECIAL: CROs & CDMOs
